The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

开始日期2024-10-10

申办/合作机构

Eli Lilly & Co.

NCT06169982

/ Completed临床1期

A Phase 1, Open-Label, Multiple-Dose Study to Investigate Steady-State Pharmacokinetics and Pharmacodynamics During a Euglycemic Clamp of LY3209590 in Participants With Type 2 Diabetes Mellitus

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

开始日期2023-12-07

申办/合作机构

Eli Lilly & Co.

NCT05914688

/ Completed临床1期

A Bioequivalence Study of Subcutaneous Injections of LY3209590 in Two Formulations in Healthy Participants

The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated.
Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.

开始日期2023-06-26

申办/合作机构

Eli Lilly & Co.

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的临床结果

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的转化医学

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的专利（医药）

登录后查看更多信息

110

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的文献（医药）

2025-07-01·Endocrinology, diabetes & metabolism

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis

Review

作者: Bhutto, Sadia Habib ; Bai, Nikeeta ; Dev, Shah ; Nancy, F. N. U. ; Abunada, Saaed ; Yusuf, Salih Abdella ; Khan, Areeba ; Bai, Sheela ; Umer, F. N. U. ; Manan, Abdul ; Zain ul Abiddin, Noshad ; Bai, Anusha ; Kumari, Usha ; Shevani, F. N. U.

ABSTRACT:

Introduction:

Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control. However, comprehensive comparisons with insulin degludec regarding continuous glucose monitoring (CGM) metrics and hypoglycaemia outcomes remain limited. This meta‐analysis evaluates these critical parameters.

Methods:

We conducted a systematic review and meta‐analysis of randomised controlled trials (RCTs) comparing once‐weekly BIF with once‐daily insulin degludec in type 1 and type 2 diabetes. Outcomes included CGM‐derived glycaemic variability, time in range, time above/below range and hypoglycaemia event rates. Data were pooled using random‐effects models, with heterogeneity assessed via I2 statistics.

Results:

Five RCTs (n = 2427) were included. BIF demonstrated comparable glycaemic variability (within‐day CV: MD = 0.06, p = 0.90; between‐day CV: MD = ‐0.26, p = 0.30) and Time in range (MD = 0.56, p = 0.27) versus degludec. However, BIF increased time spent in the mild hypoglycaemia range (54–69 mg/dL) (MD = 0.30, p = 0.0004) and clinically significant hypoglycaemia event rates (rate ratio = 1.20, p < 0.00001). Severe hypoglycaemia event rates were higher with BIF (rate ratio = 3.34, p < 0.0001). Nocturnal hypoglycaemia and time above range (> 250 mg/dL) did not differ significantly.

Conclusion:

Once‐weekly BIF provides similar overall glycaemic control to insulin degludec but with increased time in mild hypoglycaemia and higher event rates of clinically significant and severe hypoglycaemia. These findings highlight the need for individualised dosing and monitoring when transitioning to weekly insulin regimens.

2025-05-12·ACS Biomaterials Science & Engineering

Engineered Probiotics with Low Oxygen Targeting Porphyromonas gingivalis and Gingival Fibroblasts for the Treatment of Periodontitis

Article

作者: Zhong, Guannan ; Wu, Yujie ; Zheng, Kaijun ; Xu, Xiaomei ; Fan, Zhibo ; Li, Shenghong

The overuse of antibiotics has increased the prevalence of drug-resistant bacteria in periodontitis. "Sentinel" gingival fibroblasts, stimulated by pathogenic bacteria, continue to release signaling factors that affect stem cell repair and recruit immune cells, resulting in persistent inflammation in periodontal tissues, eventually leading to the loosening and loss of teeth. Periodontal pathogenic bacteria cause surface hypoxia, and gingival fibroblasts in the inflammatory microenvironment express HIF-1α, promoting hypoxic areas in periodontal pockets. No drug delivery system is available for the hypoxic region of periodontal pockets. We synthesized BI NPs via berberine (BBR) and indocyanine green (ICG) and formed BIP NPs by wrapping BI NPs with polydopamine (PDA), and the BIP NPs were delivered to the hypoxic region of the periodontal pocket by hitchhiking with the anaerobic probiotic Bifidobacterium bifidum (Bif). The BIP NPs released berberin (BBR) under near-infrared (NIR) irradiation, which inhibited the sulfur metabolism of Porphyromonas gingivalis via mild photothermal action and BBR-targeted serine acetyltransferase, resulting in a decrease in resistance to oxidative stress, thus exerting a nonantibiotic bacteriostatic effect. This mild photothermal effect facilitated the uptake of BIP NPs bygingival fibroblasts. Moreover, BBR targeted nuclear factor-erythroid 2-related factor 2 (NRF2) to reduce ferroptosis, and the gingival fibroblast supernatant modulated macrophage polarization through the NF-κB pathway. In the periodontitis rat model, Bif@BIP+NIR treatment carried the drug to deep periodontal pockets, decreasing local gingival ferroptosis and alleviating periodontitis symptoms. To summarize, engineered probiotics target low-oxygen periodontal pockets for drug delivery, P. gingivalis for nonantibiotic bacterial inhibition, and gingival fibroblasts to mitigate ferroptosis, thus alleviating periodontitis to reduce periodontitis.

2025-04-01·NUTRITION RESEARCH

Probiotic supplementation contributes to glycemic control in adults with type 2 diabetes: A systematic review and network meta-analysis

Review

作者: Wang, Hui ; Han, Mei ; Lyu, Xiaoyu ; Liu, Jingfang ; Guo, Xinyuan ; Gao, Jie ; Ma, Dengrong ; Chen, Chongyang ; Zan, Xiaohui ; Zhao, Pingping ; Suo, Hui

Type 2 diabetes mellitus (T2DM) is a chronic medical condition prevalent worldwide. Currently, probiotic therapy has demonstrated favorable outcomes in T2DM management, albeit with a lingering controversy. In this network meta-analysis (NMA), we aimed to assess and rank the glycemic control efficacy of various probiotic strains or combinations in T2DM patients. A systematic literature review was conducted across 4 major databases (PubMed, Embase, Web of Science, and Cochrane Library) including data published up to November 8, 2023, to identify randomized controlled trials (RCTs) on probiotic therapy in T2DM patients. The quality of the included RCTs was evaluated using the risk-of-bias tool version 2, while Bayesian NMA was used for analysis. The efficacy of different probiotics and their combinations was ranked based on the surface under the cumulative ranking curve (SUCRA) for various outcome indicators. This study included 1861 T2DM patients from 30 RCTs. The combination of LAC (Lactobacillus) + BIF (Bifidobacterium) + PRO (Propionibacterium) + STR (Streptococcus) exhibited the most favorable effect in reducing the fasting plasma glucose concentration and improving the homeostatic model assessment of insulin resistance (SUCRA: 88.8% and 77.3%). For reducing the concentration of glycated hemoglobin A1c, BIF (SUCRA: 93.1%) was the most effective; for improving insulin secretion, LAC + BIF (SUCRA: 84.7%) exhibited the most favorable outcome for improving insulin secretion. Cluster analysis of the 4 outcome indicators showed that the LAC + BIF + STR combination may have superior therapeutic effects. Multistrain probiotic combinations demonstrated greater glycemic control effects than single-strain probiotics. Thus, LAC + BIF + STR may be a promising probiotic combination for the treatment of T2DM. Nevertheless, owing to the inherent limitations of existing studies, further research is warranted to ascertain the long-term efficacy of probiotics.

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的新闻（医药）

14 小时之前

·医学新视点

一年少打约300针！NEJM、Lancet三连发：每周一次，长效胰岛素有效降糖

约三分之一的2型糖尿病患者在确诊后8年内需要胰岛素治疗。对低血糖的担忧和高频注射胰岛素带来的不便会让患者难以坚持按最佳剂量使用胰岛素。近年来，长效胰岛素的出现正在改变这样的挑战。Efsitora是一种每周一次皮下注射的基础胰岛素，它是一种融合蛋白，结合了新型单链胰岛素变体与人IgG2 Fc结构域。Efsitora与人胰岛素受体的结合亲和力比内源性胰岛素弱约两个数量级，这意味着这可以延长胰岛素活性，作用时间更长；同时，由于其具有较低的峰谷比，有望在整一周内帮助患者保持更稳定的血糖水平。QWINT系列研究评估了efsitora的安全性和有效性。此前发表的QWINT-2试验显示，在未接受过胰岛素治疗的2型糖尿病成人中，每周一次的efsitora治疗52周降低糖化血红蛋白（HbA1c）的效果不劣于每日一次的常用基础胰岛素；QWINT-5试验在1型糖尿病成人患者中证实了这一点。在第85届美国糖尿病协会（ADA）学术会议上，QWINT-1、QWINT-3和QWINT-4的积极结果公布，并分别同步发表于《新英格兰医学杂志》（NEJM）和《柳叶刀》（The Lancet）。这三项试验分别针对首次使用胰岛素、既往使用每日基础胰岛素、既往使用每日基础胰岛素和餐时胰岛素的2型糖尿病成年患者。在每项试验中，每周一次的efsitora在降低HbA1c方面均不劣于常用的每日基础胰岛素，且总体安全性相似。这三项研究的结果强化了efsitora通过每周给药简化胰岛素管理的潜力，意味着患者有望每年可减少近300次的胰岛素注射。QWINT-1试验：针对首次使用胰岛素患者截图来源：The New England journal of medicineQWINT-1试验是一项为期52周的开放标签、达标治疗3期试验，共795名既往未接受过胰岛素的2型糖尿病成年患者接受随机分组，按1:1接受每周一次的efsitora或每日一次的甘精胰岛素U100治疗。Efsitora采用固定剂量方案，初始剂量为每次100单位，此后每4周按需调整剂量，递增至每次150、250和400单位，以达到空腹血糖80~130 mg/dL的治疗目标。甘精胰岛素的剂量根据标准算法每周或更频繁地调整，以达到相同的血糖目标值。按治疗方案评估（无论患者依从性如何，或是否引入其他挽救治疗），efsitora组患者的平均HbA1c水平从基线时8.20%降至第52周时的7.05%，降低1.19%；而对照组患者从8.28%降至7.08%，降低1.16%；组间降幅差异为-0.03%（95%CI 0.18%~0.12%），落在非劣效性界值（0.4%）内，证实了efsitora不劣于对照胰岛素。在第52周时，efsitora组更多患者达到HbA1c水平＜7.0%（57% vs 52%）。与对照组相比，efsitora导致的低血糖事件减少了43%（RR 0.57，95%CI 0.39~0.84）：在52周时，临床显著低血糖事件（<54 mg/dL）或严重（3级）低血糖事件的估计发生率在efsitora组和对照组分别0.50次/患者-年和0.88次/患者-年。Efsitora组患者的胰岛素用量更低，平均胰岛素总剂量为289.1单位/周，而对照组为332.8单位/周，efsitora组剂量调整需求更少，中位数为2次，而对照组为8次。QWINT-3试验：针对已使用基础胰岛素治疗患者截图来源：The LancetQWINT-3是一项为期78周的开放标签、达标治疗3期临床试验，共有986名目前接受基础胰岛素治疗（不含餐时胰岛素）、最多接受三种非胰岛素降糖药物且血糖控制不佳（HbA1c水平在6.5%-10.0%之间）的2型糖尿病成年患者参与随机分组，按2:1接受每周一次efsitora（n=655）或每日一次德谷胰岛素（n=331）。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。所有患者均至少接受过一剂研究治疗，871名（88%）完成了78周的治疗。按治疗方案估计，从基线到第26周，efsitora组的平均HbA1c水平从7.80%下降至6.99%，降低0.81%；对照组患者从7.79%下降至7.08%，降低0.72%；组间降幅差异为-0.09%（95%CI 0.19~0.01），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。此外，从基线到第52周，efsitora组的HbA1c水平降幅显著更大（降低0.78% vs 降低0.59%；p=0.0014）。两组患者从基线到第78周的HbA1c水平变化相似。从连续血糖监测结果来看，在第52周前的4周监测期间，efsitora组血糖患者的24hr内血糖达标时间更高，但两组患者在26周和78周时的数据相似。安全性方面，从基线到第78周，两组患者的2级低血糖或3级（严重）低血糖事件发生率相似（RR 1.14，95%CI 0.83~1.56；p=0.43），efsitora组为0.84次/患者-年，对照组为0.74次/患者-年。Efsitora组16%患者、对照组11%患者发生了严重不良事件，其中分别有7例（1%）和1例（＜1%）与治疗有关。试验期间有9人死亡（efsitora组7人，degludec组2人），但均与研究治疗无关。QWINT-4试验：针对已使用基础胰岛素和餐时胰岛素的患者截图来源：The LancetQWINT-4是一项为期26周的开放标签、达标治疗3期试验，共730名既往使用基础胰岛素和餐时胰岛素以及最多三种非胰岛素降糖药物治疗、且HbA1c水平为7.0%-10.0%的2型糖尿病患者按1:1随机分组接受efsitora（n=365）或每日一次甘精胰岛素（n=365）治疗。治疗期间，所有参与者均接受餐时赖脯胰岛素治疗。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。按治疗方案估计，从基线到第26周，efsitora组患者的平均HbA1c水平从8.18%下降至7.17%，降低1.01%；对照组患者从8.18%下降至7.18%，降低1.00%；组间降幅差异为-0.01%（95%CI -0.14~0.12），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。在第26周前的4周连续血糖监测期间，两组患者在24hr内血糖达到、高于、低于目标区间的时间比例均没有显著差异。第26周时，efsitora组的每周胰岛素总剂量（592.9单位/周 vs 666.4单位/周）、每周基础胰岛素剂量（391.6单位/周 vs 426.6单位/周）和平均每日餐时胰岛素剂量（27.0单位/日 vs 34.6单位/日）都明显更低。治疗期间，两组患者的总体2级或3级低血糖发生率相似（6.6次/患者-年 vs 5.9次/患者-年；ERR 1.11，95%CI 0.85~1.44；p=0.44）；两组不良事件发生率相似，efsitora组7%和对照组6%的患者报告了严重不良事件。图片来源：123RF根据公开信息，礼来公司计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请，期待这款长效胰岛素早日为患者带来更便捷的血糖管理选择。推荐阅读每周一次，减重20.4%；血糖达标率超70%！NEJM连发两篇，双靶点疗法带来多重获益新药每周一次，93%中国患者成功减重，还降三高、尿酸和脂肪肝！纪立农教授领衔研究登《柳叶刀》子刊每周一次，不仅降糖，还能减重、减少使用胰岛素！《柳叶刀》子刊：新药为2型糖尿病治疗提供新选择每周一次，强效降糖！《柳叶刀》子刊：新药包含两大明星药成分，低血糖风险更低NEJM：每周一次，82%患者至少减重5%！中国患者有望在今年用上新药欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。封面图来源：123RF参考资料（可上下滑动查看）[1] Julio Rosenstock, et al., (2025). Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. The N Engl J Med, DOI: 10.1056/NEJMoa2502796[2] Julie R. Ingelfinger, Clifford J. Rosen. (2025). Weekly Insulins and Therapeutic Burden in Type 2 Diabetes. The N Engl J Med, DOI: 10.1056/NEJMe2508147[3] Athena Philis-Tsimikas, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01044-X[4] Thomas Blevins, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01069-4 External Link[5] Edith Wing-Kar Chowa, Elaine Chowa. (2025). Future of once-weekly insulins in type 2 diabetes: efficacy and safety. Lancet: DOI: 10.1016/S0140-6736(25)01098-0[6] Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials. Retrieved June 24, 2025 from https://investor.lilly.com/news-releases/news-release-details/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com分享，点赞，在看，传递医学新知

临床结果临床3期

19 小时之前

·求实药社

即将上市！礼来胰岛素周制剂3项III期研究结果公布

来源：医药魔方Info6月22日，礼来宣布了QWINT-1、QWINT-3和QWINT-4这3项III期研究的详细结果，这些研究评估了在成人2型糖尿病患者中胰岛素周制剂efsitora alfa（efsitora）的安全性和有效性。结果显示，efsitora在多项III期研究中显示出降低A1C的效果，且安全性与每日胰岛素一致。礼来计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请。胰岛素efsitora是一种融合蛋白，结合了一种新型单链胰岛素变体和人IgG2 Fc结构域。它专为每周一次皮下给药而设计，凭借其低峰谷比，有望提供更稳定的血糖水平（减少血糖波动）。这3项研究的患者分别为首次使用胰岛素、之前使用过每日基础胰岛素以及之前同时使用过每日基础胰岛素联用餐时胰岛素治疗的患者。在每项试验中，每周一次的efsitora均达到了与每日基础胰岛素相比A1C降低非劣效的主要终点。这些研究的完整结果在2025年美国糖尿病协会（ADA）第85届科学会议上公布。同时，QWINT-1（一项首创的固定剂量研究）的结果发表于《新英格兰医学杂志》，而QWINT-3和QWINT-4的结果则发表于《柳叶刀》。在QWINT-1研究中，efsitora使A1C降低了1.31%，而甘精胰岛素降低了1.27%，在第52周达到疗效估计量。在该试验中，efsitora根据需要每四周调整至四个固定剂量，以控制血糖。在QWINT-3中，efsitora使A1C降低了0.86%，而德谷胰岛素降低了0.75%，在第26周达到疗效估计量。在QWINT-4中，efsitora使A1C降低了1.07%，与甘精胰岛素的1.07%相当，在第26周达到疗效估计量。在这两项试验中，efsitora采用传统胰岛素给药方式，根据每位患者的血糖水平进行调整。在上述三项试验中，efsitora显示出与两种最常用的每日基础胰岛素治疗2型糖尿病的安全性相当。在QWINT-1中，与甘精胰岛素相比，efsitora导致的低血糖事件减少了约40%，在52周内，两组的严重或具有临床意义的低血糖事件估计综合发生率分别为0.50 vs. 0.88（患者/年）。在QWINT-3中，在78周内时，德谷胰岛素相比，上述事件的发生率分别为0.84 vs. 0.74（患者/年）。在QWINT-4中，在26周内与甘精胰岛素相比，efsitora组的严重或具有临床意义低血糖事件估计综合发生率分别为6.6 vs. 5.9（患者/年）。礼来产品开发高级副总裁Jeff Emmick博士表示：“建立在礼来胰岛素治疗领域创新传统的基础上，每周一次的efsitora可能为需要胰岛素的2型糖尿病患者带来重大进步，每年减少300多次注射。这些结果强化了每周一次efsitora通过简化治疗方案减轻胰岛素治疗负担的潜力。我们期待与监管机构合作，将这一创新带给全球患者。”免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们国内唯一！多肽、代谢与减肥药领域顶尖盛会！PMO 2025展位火热预定中！扫码立即咨询电话：13816031174（同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

临床结果临床3期临床成功临床2期

23 小时之前

·PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

Eli Lilly has shared promising phase 3 results for its once-weekly insulin candidate efsitora alfa in adults with type 2 diabetes (T2D). All three studies met their primary endpoint of non-inferior A1C reduction compared to daily basal insulin, according to data presented at this year’s American Diabetes Association Scientific Sessions. More than 4.3 million people in the UK have diabetes, with T2D accounting for around 90% of all cases. Current treatment options focus on disease management and include diet and exercise, diabetes medications and insulin therapy. It is hoped that an insulin option specifically designed for once-weekly subcutaneous administration could improve adherence rates and quality of life for patients with the chronic condition. QWINT-1, which evaluated efsitora alfa in patients using insulin for the first time, showed that Lilly’s candidate reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52. In the trial, efsitora was titrated across four fixed doses at four-week intervals, as needed for blood glucose control. In QWINT-3 and QWINT-4, which enrolled patients who had previously used daily basal insulin, and those who had previously used daily basal insulin and mealtime insulin, respectively, efsitora was given using traditional insulin dosing, with adjustments based on each patient’s glucose level. At week 26 in QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec. At the same time point in QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine. Efsitora also demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for T2D across all three studies. Jeff Emmick, senior vice president of product development at Lilly, said: “These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach.” Lilly said it is planning to submit global regulatory applications for efsitora as a treatment for adults with T2D by the end of this year. “We look forward to working with regulatory agencies to bring this innovation to patients around the world,” Emmick said.

临床结果临床3期

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	波兰	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	斯洛伐克	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	中国台湾	Eli Lilly & Co.	2022-08-12
2型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	匈牙利	Eli Lilly & Co.	2022-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05463744 (QWINT-5, CTgov)	临床3期	1型糖尿病	692	Insulin Efsitora Alfa (500 U/mL Insulin Efsitora Alfa)	蓋鹽膚繭齋鹹構顧鬱糧(醖築膚壓獵獵蓋壓選簾) = 鬱襯顧鹽廠衊艱襯蓋積遞簾蓋構膚襯淵糧積壓 (遞艱遞衊衊窪鏇繭構膚, 0.0469) 更多	-	2025-06-24
				Insulin Degludec (100 U/mL Insulin Degludec)	蓋鹽膚繭齋鹹構顧鬱糧(醖築膚壓獵獵蓋壓選簾) = 衊糧齋餘鏇夢選鏇艱夢遞簾蓋構膚襯淵糧積壓 (遞艱遞衊衊窪鏇繭構膚, 0.0463) 更多
NCT05275400 (QWINT-3, CTgov)	临床3期	2型糖尿病	986	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora)	築網憲範壓願顧鹹遞廠(網鹹糧顧範網築積齋糧) = 願鏇獵顧衊鬱鹽製範繭鏇襯壓獵淵鏇膚顧憲獵 (範製衊鏇襯繭積鏇選顧, 0.0302) 更多	-	2025-06-03
				Insulin Degludec (100 U/mL - Insulin Degludec)	築網憲範壓願顧鹹遞廠(網鹹糧顧範網築積齋糧) = 襯構願繭蓋糧鏇艱網齋鏇襯壓獵淵鏇膚顧憲獵 (範製衊鏇襯繭積鏇選顧, 0.0424) 更多
NCT05362058 (Qwint-2, CTgov)	临床3期	2型糖尿病	928	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora Alfa)	壓觸蓋衊範淵構壓衊齋(鏇遞網夢遞鹹膚蓋鹽積) = 淵繭鏇衊憲鹹廠範糧構醖簾願壓獵範遞鏇醖蓋 (糧壓廠膚齋積鬱蓋顧窪, 0.0470) 更多	-	2025-05-16
				Insulin Degludec (100 U/mL - Insulin Degludec)	壓觸蓋衊範淵構壓衊齋(鏇遞網夢遞鹹膚蓋鹽積) = 夢憲糧製蓋製顧鏇鹹醖醖簾願壓獵範遞鏇醖蓋 (糧壓廠膚齋積鬱蓋顧窪, 0.0473) 更多
NCT05462756 (QWINT-4, CTgov)	临床3期	2型糖尿病	730	Insulin Efsitora Alfa+Insulin Lispro (U100) (500 U/mL - Insulin Efsitora)	網鹹蓋衊衊積齋範範壓(夢鑰夢窪遞餘蓋餘築繭) = 膚齋積餘膚遞觸鹽淵網築壓鹹齋齋窪齋鹽餘壓 (構積築繭鑰衊餘鹽製觸, 0.0463) 更多	-	2025-04-27
				Insulin Glargine+Insulin Lispro (U100) (100 U/mL - Insulin Glargine)	網鹹蓋衊衊積齋範範壓(夢鑰夢窪遞餘蓋餘築繭) = 鏇積簾繭膚築遞衊築簾築壓鹹齋齋窪齋鹽餘壓 (構積築繭鑰衊餘鹽製觸, 0.0463) 更多
NCT05463744 (QWINT-5, Company_Website) 人工标引	临床3期	1型糖尿病	692	Insulin efsitora alfa	衊積憲網膚簾醖艱獵觸(鬱蓋選醖鹽製選鑰糧遞) = 範遞蓋願觸壓艱膚簾窪鹹餘遞築夢遞蓋膚獵顧 (製廠淵遞鹹鬱網範艱齋 ) 达到更多	非劣	2024-09-10
				Insulin degludec	衊積憲網膚簾醖艱獵觸(鬱蓋選醖鹽製選鑰糧遞) = 觸鑰鏇糧選鹹齋獵選製鹹餘遞築夢遞蓋膚獵顧 (製廠淵遞鹹鬱網範艱齋 ) 达到更多
NCT05662332 (QWINT-1, NEWS) 人工标引	临床3期	2型糖尿病	-	Efsitora alfa	醖艱淵鬱繭蓋鏇艱餘壓(構鏇選餘夢獵鑰艱顧鹹) = 鹽鹹願獵襯觸淵構鹽繭壓廠網蓋築繭壓糧蓋願 (齋蓋繭鹽壓遞鏇簾鬱壓 ) 达到更多	非劣	2024-09-09
				Insulin glargine	醖艱淵鬱繭蓋鏇艱餘壓(構鏇選餘夢獵鑰艱顧鹹) = 鏇淵構蓋構願顧築壓膚壓廠網蓋築繭壓糧蓋願 (齋蓋繭鹽壓遞鏇簾鬱壓 ) 达到更多
NCT05275400 (QWINT-3, NEWS) 人工标引	临床3期	2型糖尿病	-	Efsitora Alfa	簾網夢選壓淵顧製膚鹹(蓋衊網襯醖範窪鑰廠繭) = 鏇衊繭壓顧憲衊顧顧鏇鬱醖鬱獵壓衊網顧襯製 (鑰鏇製醖遞廠廠襯顧衊 ) 达到更多	非劣	2024-09-05
				Insulin degludec	簾網夢選壓淵顧製膚鹹(蓋衊網襯醖範窪鑰廠繭) = 願遞選壓窪繭獵淵獵齋鬱醖鬱獵壓衊網顧襯製 (鑰鏇製醖遞廠廠襯顧衊 ) 达到更多
NCT05462756 (QWINT-4, Biospace) 人工标引	临床3期	2型糖尿病	730	Efsitora	鹹獵廠醖膚糧壓衊糧網(繭鏇製廠選衊範壓顧餘) = 艱鹽淵襯窪醖壓獵夢膚窪觸鑰遞夢鹹餘襯鬱蓋 (壓積淵顧繭顧製糧鬱壓 ) 更多	积极	2024-05-16
				Glargine	鹹獵廠醖膚糧壓衊糧網(繭鏇製廠選衊範壓顧餘) = 醖製鑰鬱網糧網壓繭齋窪觸鑰遞夢鹹餘襯鬱蓋 (壓積淵顧繭顧製糧鬱壓 ) 更多
NCT05362058 (Qwint-2, Biospace) 人工标引	临床3期	2型糖尿病	928	Efsitora alfa (Efsitora)	網衊蓋淵憲製積窪願鬱(糧鹹範遞構淵衊糧繭築) = 鑰艱觸築製觸壓鏇構範齋糧鏇淵餘衊衊網網夢 (顧衊窪襯鬱窪鏇壓衊獵 ) 达到更多	非劣	2024-05-16
				Degludec (Tresiba)	網衊蓋淵憲製積窪願鬱(糧鹹範遞構淵衊糧繭築) = 遞積壓遞鹽淵夢簾壓襯齋糧鏇淵餘衊衊網網夢 (顧衊窪襯鬱窪鏇壓衊獵 ) 达到更多
NCT04450394 \| NCT03736785 \| NCT04450407 (phase 2, EASD2023)	临床2期	-	912	Once-weekly insulin efsitora alfa	膚顧築窪積獵襯願襯膚(壓艱憲築觸繭衊膚鹽構) = 簾遞網壓齋廠廠鬱獵膚簾壓鹹構憲獵獵網夢構 (製網壓構製廠繭壓選壓 ) 更多	积极	2023-10-03
				Once daily degludec	膚顧築窪積獵襯願襯膚(壓艱憲築觸繭衊膚鹽構) = 衊齋鹽膚範齋鏇醖鑰顧簾壓鹹構憲獵獵網夢構 (製網壓構製廠繭壓選壓 ) 更多